CoChat
Sign Up
Cited by 42Psychopathy, Forensic Psychiatry, Sexual OffendingSexuality, Behavior, and TechnologySchizophrenia research and treatment

Protocols for the use of cyproterone, medroxyprogesterone, and leuprolide in the treatment of paraphilia

Open access
Reilly, Dan R, Delva, Nicholas J, Hudson, Robert W·2000·The Canadian Journal of Psychiatry
DOI 10.1177/070674370004500608
Open this paper in CoChat — free accountOpen PDF

Abstract

Objective: To propose a protocol for minimizing medical complications associated with the use of cyproterone, medroxyprogesterone, and depot leuprolide to treat paraphilia. Method: Review of the relevant literature. Results: Certain patient populations should not be treated with these medications, and medical complications associated with each can be detected early and avoided. Conclusions: For each drug, a series of screening tests prior to use and scheduled testing during use can minimize potential medical complications.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/070674370004500608

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • All three agents (progestogens, antiandrogens, GnRH analogues) are associated with potential adverse effects such as precipitation or aggravation of cardiac conditions, gynaecomastia, weight gain, hot flushes, or depression.

    “All three agents are associated with potential adverse effects (Reilly 2000), such as precipitation or aggravation of cardiac conditions (De Voogt 1986; Pierce 1995), gynaecomastia, weight gain, hot flushes, or depression (Grubin 2008).”

    From Pharmacological interventions for those who have sexually offended or are at risk of offending (2015) · cites this paper as Reilly 2000

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 27

  1. I. Santen RJ. The testis. In: Felig P, Baxter JD, Frohman LA, editors. Endocrinology and metabolism. 3rd ed. New York: McGraw-Hill; 1995. p 885-972.
  2. Jackson GL, Kuehl D. Rhim TJ. Testosterone inhibits gonadotropin-releasing hor- mone pulse frequency in the male sheep. Bioi Reprod 1991;24: 188-94.
  3. Santen RJ, Demers LM, Max DT, SmithJ, SteinBS, GlodenLM. Long term effects ofadministration of a gonadotropin releasing hormone superagonist analog in men with prostatic carcinoma. J Clin Endocrinol Metab 1984;55:397-403.
  4. Geller J. Overview of enzyme inhibitors and anti-androgen in prostatic cancer. J AndroI1991;12:364-70.
  5. Kappy M, Stuart T, Perelman A, Clemons R. Suppresion of gonadotropin secretion by a long acting gonadotropin releasing hormone analog (leuprolide acetate, lupron depot) in children with precocious puberty. J Clin Endocrinol Metab 1989;69: 1087-9.
  6. Neumann F, Kalmus J. Cyproterone acetate in the treatment of sexual disorders: pharmacological base and clinical experience. Experimental and Clinical Endocri- nology 1991;98(2):71-80.
  7. Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogues.N Engl J Med 1990;324:93-103.
  8. II. Thibaut F, Cordier B, Kuhn 1M. Effect of a long-lasting gonadotrophin hormone- releasing hormone agonist in six cases of severe male paraphilia. Acta Psychiatr Scand 1993;87:445-50.
  9. Rosier A, Witztum E. Treatment of men with paraphilia with a long-acting ana- logue of gonadotropin-releasing hormone. N Engl J Med 1998;338:416-22.
  10. Cooper AJ, Sandhu S, Losztyn S, Cemovsky Z. A double-blind placebo controlled trial of medroxyprogestersone acetate and cyproterone acetate with seven pedo- philes. Can J Psychiatry 1992;37:687-93.
  11. Rao MV, Roy GK, Prasannalata SN. Effect ofmedroxyprogesterone acetate and testosterone enanthate on vas deferens ofrats. Indian J Exp Bioi 1998;36:157-61.
  12. Avari KM, Bhiwgade DA. Effect ofdepot medroxyprogesterone acetate and testos- terone anathate on the testis of albino rats: ultrastructural and biochemical studies. Indian J Exp Bioi 1992;30: 1118-27.
  13. Vallis K, Waxman J. Tumour flare in hormone therapy. In: Stroll BA, editor. Endo- crine management of cancer. 2: contemporary therapy. Basel (Switzerland): Karger; 1988. p 144-52.
  14. Morsi A, Jamal S, Silverberg 1OH. Pituitary apoplexy after leuprolide administra- tion for carcinoma of the prostate. Clin EndocrinoI1996;44: 121-4.
  15. Saruki K, Sekihara T, Mashimo M, Matsuo H, Sekiguchi H. Leuprorelin acetate blood levels and dialysance after the administration of sustained-release leuprorelin acetate in a dialysis case complicated by prostate cancer. Prostate 1998;34: 191-4.
  16. Roila F. Crino L. Carloni G. Natalini G. Cyproterone acetate: hepatotoxicity and prostate cancer treatment. Ann Oncol 1993;4:70 I.
  17. Parys BT. Hamid S. Thomson RG. Severe hepatocellular dysfunction following cyproterone acetate therapy. Br J UroI1991;67:312-3.
  18. Smith JA. A prospective comparison for symptomatic hot flashes following endo- crine therapy for carcinoma of the prostate. J Urol 1994; 152: 132-4.
  19. Schot LPC, Schuurs AHWM. Pathophysiology of bone loss in castrated animals. .I Steroid Biochem Mol Bioi 1990;37:461-5.
  20. Stepan 11. Lachman M. Zverina J. Pacovsky Y. Baylink DJ. Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodel- ling. J Clin Endocrinol Metab 1989;69:523-7.
  21. Li M. Jee WS. Ke HZ. Tang LY. Ma YF. Liang XG. and others. Prostaglandin E2 administration prevents bone loss induced by orchidectomy in rats. J Bone Miner Res 1995;10:66-73.
  22. Schot LP. Schuurs AH. Sex steroids and osteoporosis: effects of deficiencies and substitute treatments. J Steroid Biochem Mol Bioi 1990;37: 167-88.
  23. Jackson IA, Michael K. Osteoporosis in men: diagnosis. pathophysiology, and pre- vention. Medicine 1990;69: 137-52.
  24. Sotanicmi EA, Hynnynen T, Ahlqvist .I, Ahokas .IT. Puoskari U, Pelkonen I. Ef- fects ofmedroxyprogestcrone on the liver function and drug metabolism ofpatients with biliary cirrhosis and chronic active hepatitis. J Med 1978;9: 117-28.
  25. Rautio A, Sotanicmi EA. Pelkouen O. Luoma PY. Treatment of alcoholic cirrhosis with enzyme inducers. Clin Pharmacol Ther 1980;28:629-37.
  26. Abramson FP, Moore CF Sr, Hill MD. Medroxyprogesterone acetate does not in- duce antipyrine clearance and only weakly increases alpha l-acid glycoprotein in beagle dogs. Research Communications in Chemical Pathology and Pharmacology 1986;53:65-78.
  27. Gotz YP, Dolly FR, Block AJ. Intluence of'rnedroxyprogcsterone on theophylline disposition . .I Clin Pharmacol 1983;23:281-4.

Cited by

Sorted by citations

Authors
Reilly, D. R., Delva, N. J., & Hudson, R. W.
Affiliations
  • University of Ottawa (CA)
  • Queen's University (CA)
Venue
The Canadian Journal of Psychiatry
Publisher
SAGE Publications
Published
2000-08
Volume
45
Issue
6
Pages
559-563
ISSN
  • 0706-7437 (ISSN-L)
  • 1497-0015
DOI
10.1177/070674370004500608
OpenAlex
W98454650
Cited by
42
References
3
Citations by year
2021: 1 · 2020: 3 · 2018: 1 · 2017: 2 · 2016: 1 · 2015: 3 · 2014: 4
FWCI
4.49
Type
journal article
Language
en
Open access
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • The Canadian Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychopathy, Forensic Psychiatry, Sexual Offending
  • Social Sciences › Psychology › Clinical Psychology › Sexuality, Behavior, and Technology
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
paraphilias, cyproterone, medroxyprogesterone, hormone therapy, medical complications, screening test, treatment protocols, contraindications
MeSH terms
Administration, Oral, Androgen Antagonists, Dose-Response Relationship, Drug, Drug Administration Schedule, Humans, Injections, Intramuscular, Male, Medroxyprogesterone, Paraphilic Disorders, Leuprolide, Cyproterone Acetate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review